Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:


Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Tasisulam

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Tasisulam: Patents, clinical trial progress, indications

Tasisulam is an investigational drug.

There have been 11 clinical trials for Tasisulam. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2009.

The most common disease conditions in clinical trials are Melanoma, Fallopian Tube Neoplasms, and Carcinoma, Renal Cell. The leading clinical trial sponsors are Eli Lilly and Company and [disabled in preview].

There are six US patents protecting this investigational drug and fifty-four international patents.

Recent Clinical Trials for Tasisulam
A Tasisulam and Midazolam Drug Interaction Study in Cancer PatientsEli Lilly and CompanyPhase 1
A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or LymphomaEli Lilly and CompanyPhase 1
A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic MelanomaEli Lilly and CompanyPhase 3

See all Tasisulam clinical trials

Clinical Trial Summary for Tasisulam

Top disease conditions for Tasisulam
Top clinical trial sponsors for Tasisulam

See all Tasisulam clinical trials

US Patents for Tasisulam

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tasisulam   Start Trial Thiophene-amd thiazolesulfonamides as antineoplastic agents Eli Lilly and Company (Indianapolis, IN)   Start Trial
Tasisulam   Start Trial Thiophene-and thiazolesulfonamides as antineoplastic agents Eli Lilly and Company (Indianapolis, IN)   Start Trial
Tasisulam   Start Trial TGF-beta receptor inhibitors to enhance direct reprogramming The General Hospital Corporation (Boston, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.